Health Care ETFs Remain Unfazed by Price Reductions from Major Pharmaceutical Companies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: Benzinga
Impact of Drug Pricing Deals: Big pharmaceutical companies are negotiating with the U.S. government to lower Medicaid drug prices, but analysts believe the financial impact on these companies may be less severe than initially feared.
Medicaid's Role in Drug Pricing: Medicaid accounts for about 10% of U.S. prescription drug spending and often secures significant discounts, which helps mitigate concerns over pricing pressures on pharmaceutical companies.
Resilience of Health Care ETFs: Diversified health care ETFs, such as the Health Care Select Sector SPDR Fund and Vanguard Health Care ETF, are performing well and provide a buffer against potential volatility from drug pricing news.
Pharma-Specific ETFs and Diversification: While specialized pharmaceutical ETFs may face more direct impacts from pricing negotiations, their diversified structures help reduce risks associated with individual companies, allowing them to remain stable amidst market fluctuations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 125.970
Low
105.00
Averages
137.88
High
154.00
Current: 125.970
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, and others. It also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. It has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The Company also owns an antibody-drug conjugates (ADCs) platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead's Trodelvy Receives FDA Approval for Expanded Use
- FDA Approval for New Indication: Gilead's Trodelvy has received FDA approval as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone for PD-(L)1-ineligible patients or in combination with Keytruda for PD-L1-positive tumors, marking a significant elevation in its role in breast cancer treatment.
- Clinical Data Support: This decision is underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, further solidifying Trodelvy's position in breast cancer care and potentially driving Gilead's oncology investment narrative forward.
- Market Risk Considerations: Despite the positive signal from Trodelvy's approval for Gilead's oncology growth, there remain execution risks related to pricing and access in the market, particularly in the face of rising policy and competitive pressures that could impact future market performance.
- Revenue Expectations: Gilead projects $34.5 billion in revenue and $10.8 billion in earnings by 2029, necessitating a 5.1% annual revenue growth and a $1.6 billion increase in earnings, with Trodelvy's success directly influencing these growth expectations.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
FDA Approves Trodelvy for First-Line Treatment of Metastatic TNBC
- FDA Approval for New Indication: Gilead Sciences announced that its cancer drug Trodelvy has received FDA approval for first-line treatment of metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Data Support: The FDA approval is based on data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, demonstrating that Trodelvy monotherapy reduces the risk of disease progression or death by 38%, while its combination with Keytruda lowers this risk by 35%, indicating substantial clinical efficacy.
- Significant Market Potential: With mTNBC accounting for approximately 15% of all breast cancers and a five-year survival rate of only 12%, the approval of Trodelvy provides a new treatment option for this high-risk patient population, which is expected to drive future sales growth for the company.
- Sales Growth Trend: GILD's Trodelvy achieved sales of $1.40 billion in 2025, a 6% increase from $1.32 billion the previous year, reflecting strong market performance and sustained demand for the drug, further solidifying Gilead's position in the biopharmaceutical sector.
See More
QQQ ETF Outperforms S&P 500 Over Last Decade
- Outstanding Historical Performance: Over the past decade, the Invesco QQQ Trust ETF has achieved a return of 570%, significantly outperforming the S&P 500's 255%, highlighting its strong appeal among investors, particularly driven by tech stocks.
- Diversified Portfolio: While QQQ is tech-heavy (66.9%), it also includes non-tech companies like Walmart and Costco, ensuring that other sectors can provide support during tech industry fluctuations, thereby enhancing investment stability.
- AI Boom Contribution: Much of QQQ's strong performance is attributed to the current AI boom, with nine of its component companies valued at over $1 trillion, driving overall valuation increases and further solidifying its market leadership.
- Confidence in Future Growth: Despite high valuations in tech stocks, the diverse growth opportunities of QQQ's holdings, such as cloud computing and biotech, instill confidence in investors for continued outperformance over the next decade.
See More
FDA Approves Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
- FDA Approval: Gilead Sciences announced that its drug Trodelvy has received FDA approval as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, marking a significant advancement in cancer therapy.
- Clinical Trial Support: Data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 studies indicate that Trodelvy monotherapy reduces the risk of disease progression or death by 38% in patients ineligible for PD-L1 inhibitors, demonstrating substantial efficacy.
- Combination Therapy Benefits: In the ASCENT-04 study, the combination of Trodelvy and Keytruda reduced the risk of disease progression or death by 35% in PD-L1-positive patients, further solidifying its position in treatment protocols.
- Preferred Treatment Status: The National Comprehensive Cancer Network (NCCN) lists Trodelvy as a preferred first-line treatment option for mTNBC, and it is approved in over 60 countries for second-line or later metastatic triple-negative breast cancer, highlighting its global recognition and application potential.
See More
QQQ ETF Outperforms S&P 500 with Strong Tech Growth
- Significant Returns: The Invesco QQQ Trust ETF has achieved a remarkable 570% return over the past decade, significantly outperforming the S&P 500's 255%, indicating its strong appeal among investors and attracting more capital inflow.
- Tech Sector Dominance: With tech stocks comprising 66.9% of QQQ, the 'Magnificent Seven' including Nvidia and Apple account for nearly 35% of the ETF, highlighting QQQ's heavy reliance on tech growth while providing support from other sectors.
- AI Boom Driving Growth: The current AI surge has propelled nine component companies of QQQ to valuations exceeding $1 trillion, reflecting the strong performance of tech stocks that drive QQQ, although high valuations may pose risks of pullbacks.
- Diverse Investment Opportunities: QQQ is not solely dependent on the tech sector, encompassing various fields such as cloud computing and biotech, and while future annual returns may not reach 21%, it is expected to continue outperforming other investment options in the market.
See More
Gilead's Trodelvy Receives FDA Approval for Expanded Use
- FDA Approval for New Indication: Gilead's Trodelvy has received FDA approval as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone for PD-(L)1-ineligible patients or in combination with Keytruda for PD-L1-positive tumors, marking a significant elevation in its role in breast cancer treatment.
- Clinical Data Support: This decision is underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, further solidifying Trodelvy's position in breast cancer care and potentially driving Gilead's oncology investment narrative forward.
- Market Risk Considerations: Despite the positive signal from Trodelvy's approval for Gilead's oncology growth, there remain execution risks related to pricing and access in the market, particularly in the face of rising policy and competitive pressures that could impact future market performance.
- Revenue Expectations: Gilead projects $34.5 billion in revenue and $10.8 billion in earnings by 2029, necessitating a 5.1% annual revenue growth and a $1.6 billion increase in earnings, with Trodelvy's success directly influencing these growth expectations.
See More
Biotech Sector Update: FDA and EU Approvals
- FDA Drug Approval: Ionis Pharmaceuticals' TRYNGOLZA received FDA approval as an adjunct therapy for severe hypertriglyceridemia, with Phase 3 studies showing up to a 72% reduction in triglycerides, significantly improving patient health and expected to drive revenue growth.
- EU Therapy Approval: Merck's Keytruda in combination with Padcev received European approval for muscle-invasive bladder cancer, with Phase 3 trial data indicating a 60% improvement in event-free survival, laying the groundwork for market expansion in Europe.
- New Treatment Launch: Gilead Sciences' Trodelvy was approved by the FDA as a first-line treatment for metastatic triple-negative breast cancer, demonstrating a 38% reduction in the risk of disease progression or death, projected to boost sales to $1.4 billion in 2025.
- Strategic Restructuring and Layoffs: ADC Therapeutics announced a 17% workforce reduction, expected to save $10 million annually, aimed at reallocating resources to advance the ZYNLONTA project, although facing $3 million in severance costs in the short term, it is expected to enhance long-term financial health.
See More
FDA Approves Trodelvy for First-Line Treatment of Metastatic TNBC
- FDA Approval for New Indication: Gilead Sciences announced that its cancer drug Trodelvy has received FDA approval for first-line treatment of metastatic triple-negative breast cancer (mTNBC), marking a significant advancement in the company's oncology portfolio.
- Clinical Trial Data Support: The FDA approval is based on data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, demonstrating that Trodelvy monotherapy reduces the risk of disease progression or death by 38%, while its combination with Keytruda lowers this risk by 35%, indicating substantial clinical efficacy.
- Significant Market Potential: With mTNBC accounting for approximately 15% of all breast cancers and a five-year survival rate of only 12%, the approval of Trodelvy provides a new treatment option for this high-risk patient population, which is expected to drive future sales growth for the company.
- Sales Growth Trend: GILD's Trodelvy achieved sales of $1.40 billion in 2025, a 6% increase from $1.32 billion the previous year, reflecting strong market performance and sustained demand for the drug, further solidifying Gilead's position in the biopharmaceutical sector.
See More
QQQ ETF Outperforms S&P 500 Over Last Decade
- Outstanding Historical Performance: Over the past decade, the Invesco QQQ Trust ETF has achieved a return of 570%, significantly outperforming the S&P 500's 255%, highlighting its strong appeal among investors, particularly driven by tech stocks.
- Diversified Portfolio: While QQQ is tech-heavy (66.9%), it also includes non-tech companies like Walmart and Costco, ensuring that other sectors can provide support during tech industry fluctuations, thereby enhancing investment stability.
- AI Boom Contribution: Much of QQQ's strong performance is attributed to the current AI boom, with nine of its component companies valued at over $1 trillion, driving overall valuation increases and further solidifying its market leadership.
- Confidence in Future Growth: Despite high valuations in tech stocks, the diverse growth opportunities of QQQ's holdings, such as cloud computing and biotech, instill confidence in investors for continued outperformance over the next decade.
See More
FDA Approves Trodelvy for First-Line Treatment of Triple-Negative Breast Cancer
- FDA Approval: Gilead Sciences announced that its drug Trodelvy has received FDA approval as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, marking a significant advancement in cancer therapy.
- Clinical Trial Support: Data from the ASCENT-03 and ASCENT-04/KEYNOTE-D19 studies indicate that Trodelvy monotherapy reduces the risk of disease progression or death by 38% in patients ineligible for PD-L1 inhibitors, demonstrating substantial efficacy.
- Combination Therapy Benefits: In the ASCENT-04 study, the combination of Trodelvy and Keytruda reduced the risk of disease progression or death by 35% in PD-L1-positive patients, further solidifying its position in treatment protocols.
- Preferred Treatment Status: The National Comprehensive Cancer Network (NCCN) lists Trodelvy as a preferred first-line treatment option for mTNBC, and it is approved in over 60 countries for second-line or later metastatic triple-negative breast cancer, highlighting its global recognition and application potential.
See More
QQQ ETF Outperforms S&P 500 with Strong Tech Growth
- Significant Returns: The Invesco QQQ Trust ETF has achieved a remarkable 570% return over the past decade, significantly outperforming the S&P 500's 255%, indicating its strong appeal among investors and attracting more capital inflow.
- Tech Sector Dominance: With tech stocks comprising 66.9% of QQQ, the 'Magnificent Seven' including Nvidia and Apple account for nearly 35% of the ETF, highlighting QQQ's heavy reliance on tech growth while providing support from other sectors.
- AI Boom Driving Growth: The current AI surge has propelled nine component companies of QQQ to valuations exceeding $1 trillion, reflecting the strong performance of tech stocks that drive QQQ, although high valuations may pose risks of pullbacks.
- Diverse Investment Opportunities: QQQ is not solely dependent on the tech sector, encompassing various fields such as cloud computing and biotech, and while future annual returns may not reach 21%, it is expected to continue outperforming other investment options in the market.
See More
